Advances in allergen immunotherapy in 2015

• Published in: Journal of allergy and clinical immunology Vol. 138; no. 5; pp. 1284 - 1291
• Main Author: Bush, Robert K., MD
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.11.2016; Elsevier Limited
• Subjects: Allergen immunotherapy; Allergy and Immunology; Animals; Asthma; Asthma - therapy; Biomarkers; Clinical trials; Desensitization, Immunologic; Disease; Drug therapy; Food; Food allergies; Food Hypersensitivity - therapy; Humans; Immunology; Immunotherapy; Patients; Rhinitis, Allergic - therapy; Studies; Vaccines - therapeutic use; Epicutaneous immunotherapy; APT; SPIRE; Environmental exposure chamber; HDM; immunotherapy; Synthetic immunoregulatory T-cell epitope; Regulatory T; clinical trials; SCIT; Ovalbumin; EEC; SLIT; β-Lactoglobulin; Treg; Subcutaneous immunotherapy; House dust mite; AIT; Sublingual immunotherapy; Oral immunotherapy; EPIT; Atopy patch test; OIT; OVA; Allergen immunotherapy; BLG
• ISSN: 0091-6749; 1097-6825
• DOI: 10.1016/j.jaci.2016.09.007

The year 2015 saw a significant number of advances in allergen immunotherapy (AIT), and several of these are reviewed in this report. Although AIT has been used for more than 100 years, investigations into optimal treatment approaches and mechanisms are ongoing. Among the highlights was a report by an international group of experts who reviewed AIT guidelines from the major specialty societies and addressed potential unmet needs. Herein, advances in the effectiveness, safety, and mechanisms of sublingual and oral immunotherapy are reviewed. Development of hypoallergenic vaccines to enhance safety, newer routes and regimens to improve efficacy, and biomarkers to monitor immunotherapy are also discussed.